Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction
Status:
RECRUITING
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
Single-center, double-blind, randomized, controlled intervention study of the effect of correction of bacterial overgrowth syndrome in the small intestine (SIBO) on cardiac function in patients with heart failure with preserved ejection fraction (HFpEF) (SIBO-HFpEF). The aim of the study is to evaluate the efficacy and safety of rifaximin in patients with HFpEF and SIBO.
Phase:
NA
Details
Lead Sponsor:
I.M. Sechenov First Moscow State Medical University